Skip to main content
SpringerLink
Log in

Chemo-, zielgerichtete und Immuntherapie

Palliative Systemtherapie von Kopf-Hals-Plattenepithelkarzinomen

  • Zertifizierte Fortbildung
  • Published:
InFo Hämatologie + Onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1

© USZ

2

Literatur

  1. Mody MD et al. Head and neck cancer. Lancet. 2021;398(10318):2289-99

  2. Vokes EE et al. Head and neck cancer. N Engl J Med. 1993;328(3):184-94

  3. Wyss A et al. Cigarette, cigar, and pipe smoking and the risk of head and neck cancers: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Am J Epidemiol. 2013;178(5):679-90

  4. Chaturvedi AK et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011;29(32):4294-301

  5. De Stefani E et al. Hard liquor drinking is associated with higher risk of cancer of the oral cavity and pharynx than wine drinking. A case-control study in Uruguay. Oral Oncol. 1998;34(2):99-104

  6. Scheffner M et al. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell. 1993;75(3):495-505

  7. Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015;517(7536):576-82

  8. Tiwana MS et al. 25 year survival outcomes for squamous cell carcinomas of the head and neck: population-based outcomes from a Canadian province. Oral Oncol. 2014;50(7):651-6

  9. Osazuwa-Peters N et al. Suicide risk among cancer survivors: Head and neck versus other cancers. Cancer. 2018;124(20):4072-9

  10. Jacobs C et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol. 1992;10(2):257-63

  11. Gibson MK et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2005;23(15):3562-7

  12. Kalyankrishna S, Grandis JR. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol. 2006;24(17):2666-72

  13. Ferris RL et al. Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J Clin Oncol. 2010;28(28):4390-9

  14. Vermorken JB et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359(11):1116-27

  15. Guigay J et al. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2021;22(4):463-75

  16. Tsakonas G et al. Randomized Phase II Study with Cetuximab in Combination with 5-FU and Cisplatin or Carboplatin vs. Cetuximab in Combination with Paclitaxel and Carboplatin for Treatment of Patients with Relapsed or Metastatic Squamous Cell Carcinoma of the Head and Neck (CETMET Trial). Cancers (Basel). 2020;12(11):3110

  17. Vermorken JB et al. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Lancet Oncol. 2013;14(8):697-710

  18. Argiris A et al. Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer. J Clin Oncol. 2019;37(34):3266-74

  19. Forster MD, Devlin MJ. Immune Checkpoint Inhibition in Head and Neck Cancer. Front Oncol. 2018;8:310

  20. Riley JL. PD-1 signaling in primary T cells. Immunol Rev. 2009;229(1):114-25

  21. Burtness B et al. Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score. J Clin Oncol. 2022;40(21):2321-32

  22. Burtness B et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394(10212):1915-28

  23. Harrington KJ et al. Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study. J Clin Oncol. 2023;41(4):790-802

  24. Dzienis MR et al. 651O - Pembrolizumab (pembro) + carboplatin (carbo) + paclitaxel (pacli) as first-line (1L) therapy in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Phase VI KEYNOTE-B10 study. Ann Oncol. 2022;33(Suppl_7):S295-S322

  25. Haddad RI et al. Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651. J Clin Oncol. 2023;41(12):2166-80

  26. Szturz P et al. How Standard Is Second-Line Cetuximab in Recurrent or Metastatic Head and Neck Cancer in 2017? J Clin Oncol. 2017;35(20):2229-31

  27. Ferris RL et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016;375(19):1856-67

  28. Cohen EEW et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet. 2019;393(10167):156-67

  29. Guardiola E et al. Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer. Eur J Cancer. 2004;40(14):2071-6

  30. Vermorken JB et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol. 2007;25(16):2171-7

  31. Foster CC et al. Definition, Biology, and History of Oligometastatic and Oligoprogressive Disease. Cancer J. 2020;26(2):96-9

  32. Bonomo P et al. Re-irradiation for oligoprogression under Nivolumab in recurrent head and neck squamous cell carcinoma: A case report. Clin Transl Radiat Oncol. 2020;23:16-9

  33. Sindhu KK et al. Oligoprogression of Solid Tumors on Immune Checkpoint Inhibitors: The Impact of Local Ablative Radiation Therapy. Biomedicines. 2022;10(10):2481

  34. Soulieres D et al. Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncol. 2017;18(3):323-35

  35. Ho AL et al. Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations. J Clin Oncol. 2021;39(17):1856-64

Download references

Author information

Authors and Affiliations

  1. Klinik für Medizinische Onkologie und Hämatologie USZ, Universitätsspital Zürich, Rämistrasse 100, 8091, Zürich, Schweiz

    Tomas Brezina &  Anja Lorch

Authors
  1. Tomas Brezina
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anja Lorch
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Der Autor und die Autorin erklären, dass sie sich bei der Erstellung des Beitrages von keinen wirtschaftlichen Interessen leiten ließen. Sie legen folgende potenzielle Interessenkonflikte offen: keine.

Der Verlag erklärt, dass die inhaltliche Qualität des Beitrags durch zwei unabhängige Gutachten bestätigt wurde. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung.

Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheitsbildes geeignet sind.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Brezina, T., Lorch, A. Palliative Systemtherapie von Kopf-Hals-Plattenepithelkarzinomen. InFo Hämatol Onkol 26, 40–49 (2023). https://doi.org/10.1007/s15004-023-0011-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-023-0011-1

Search

Navigation